Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

For CTOs and senior technology leaders, cloud cost optimization is no longer a back-office exercise—it’s a boardroom priority ...

Our lab data proves you can find top-performing cordless vacuums with long-lasting batteries and strong suction without ...

The summit comes at a critical time, as data show New Jersey’s older adults are increasingly vulnerable to the impact of opioids and other prescription drugs. From January to April 2025, adults aged ...

Four zodiac signs are attracting significant abundance and luck on Tuesday, September 16, 2025. Are you ready for a turning ...

Healthy teams aren't a nice-to-have. They are a business imperative. Research shows that unhealthy teams cost companies through burnout, lost produ ...

CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...

At this grand event focusing on the deep integration of technology and innovation, Xu Yihan, Senior Executive Vice President ...